# Medical Properties Trust Inc: financial statements, quarterly

MPT · NYSE · CIK 1287865 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mpt.md) · [Financials](/companies/mpt/financials.md) · [Filings](/companies/mpt/filings.md) · [Insiders](/companies/mpt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mpt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [337](/filings/0000950170-24-094888.md) | [307](/filings/0000950170-24-125623.md) | [(122) d](/filings/0001193125-26-073587.md) | [271](/filings/0000950170-25-068203.md) | [267](/filings/0000950170-25-106022.md) | [226](/filings/0001193125-25-272324.md) | [232 d](/filings/0001193125-26-073587.md) | [224](/filings/0001193125-26-214700.md) | [240](/filings/0000950170-25-106022.md) | [238](/filings/0001193125-25-272324.md) | [270 d](/filings/0001193125-26-073587.md) | [252](/filings/0001193125-26-214700.md) |
| Cost of revenue | $m | [(28.7) d](/filings/0000950170-23-040734.md) | [28.8 d](/filings/0000950170-23-062169.md) | [(72.1) d](/filings/0000950170-24-023248.md) | [40.9](/filings/0000950170-24-065929.md) | [4.3 d](/filings/0000950170-24-094888.md) | [7.8 d](/filings/0000950170-24-125623.md) | [21.1 d](/filings/0000950170-25-030989.md) | [81.4](/filings/0000950170-25-068203.md) | [19.8 d](/filings/0000950170-25-106022.md) | [(22.3) d](/filings/0001193125-25-272324.md) | [11.4 d](/filings/0001193125-26-073587.md) | [97.3](/filings/0001193125-26-214700.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [104](/filings/0000950170-24-094888.md) | [107](/filings/0000950170-24-125623.md) | [102 d](/filings/0001193125-26-073587.md) | [109](/filings/0000950170-25-068203.md) | [101](/filings/0000950170-25-106022.md) | [106](/filings/0001193125-25-272324.md) | [101 d](/filings/0001193125-26-073587.md) | [116](/filings/0001193125-26-214700.md) | [130](/filings/0000950170-25-106022.md) | [132](/filings/0001193125-25-272324.md) | [132 d](/filings/0001193125-26-073587.md) | [133](/filings/0001193125-26-214700.md) |
| Income tax | $m | [(148)](/filings/0000950170-24-094888.md) | [10.1](/filings/0000950170-24-125623.md) | [4.0 d](/filings/0001193125-26-073587.md) | [10.9](/filings/0000950170-25-068203.md) | [14.6](/filings/0000950170-25-106022.md) | [9.0](/filings/0001193125-25-272324.md) | [9.6 d](/filings/0001193125-26-073587.md) | [9.4](/filings/0001193125-26-214700.md) | [9.8](/filings/0000950170-25-106022.md) | [10.9](/filings/0001193125-25-272324.md) | [8.5 d](/filings/0001193125-26-073587.md) | [(32.8)](/filings/0001193125-26-214700.md) |
| Net income | $m | [(42.0)](/filings/0000950170-24-094888.md) | [117](/filings/0000950170-24-125623.md) | [(664) d](/filings/0001193125-26-073587.md) | [(876)](/filings/0000950170-25-068203.md) | [(321)](/filings/0000950170-25-106022.md) | [(801)](/filings/0001193125-25-272324.md) | [(413) d](/filings/0001193125-26-073587.md) | [(118)](/filings/0001193125-26-214700.md) | [(98.4)](/filings/0000950170-25-106022.md) | [(77.7)](/filings/0001193125-25-272324.md) | [17.3 d](/filings/0001193125-26-073587.md) | [32.8](/filings/0001193125-26-214700.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0000950170-24-094888.md) | [0.19](/filings/0000950170-24-125623.md) | not reported | [(1.46)](/filings/0000950170-25-068203.md) | [(0.54)](/filings/0000950170-25-106022.md) | [(1.34)](/filings/0001193125-25-272324.md) | not reported | [(0.20)](/filings/0001193125-26-214700.md) | [(0.16)](/filings/0000950170-25-106022.md) | [(0.13)](/filings/0001193125-25-272324.md) | not reported | [0.05](/filings/0001193125-26-214700.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0000950170-24-094888.md) | [0.19](/filings/0000950170-24-125623.md) | not reported | [(1.46)](/filings/0000950170-25-068203.md) | [(0.54)](/filings/0000950170-25-106022.md) | [(1.34)](/filings/0001193125-25-272324.md) | not reported | [(0.20)](/filings/0001193125-26-214700.md) | [(0.16)](/filings/0000950170-25-106022.md) | [(0.13)](/filings/0001193125-25-272324.md) | not reported | [0.05](/filings/0001193125-26-214700.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.3](/filings/0000950170-24-094888.md) | [0.3](/filings/0000950170-24-125623.md) | [0.3](/filings/0001193125-26-073587.md) | [0.2](/filings/0000950170-25-068203.md) | [0.6](/filings/0000950170-25-106022.md) | [0.3](/filings/0001193125-25-272324.md) | [0.3](/filings/0001193125-26-214700.md) | [0.7](/filings/0001193125-26-214700.md) | [0.5](/filings/0000950170-25-106022.md) | [0.4](/filings/0001193125-25-272324.md) | [0.5](/filings/0001193125-26-214700.md) | [0.4](/filings/0001193125-26-214700.md) |
| Total assets | $bn | [19.2](/filings/0000950170-23-040734.md) | [19.0](/filings/0000950170-23-062169.md) | [18.3](/filings/0000950170-25-030989.md) | [17.3](/filings/0000950170-24-065929.md) | [16.2](/filings/0000950170-24-094888.md) | [15.2](/filings/0000950170-24-125623.md) | [14.3](/filings/0001193125-26-073587.md) | [14.9](/filings/0000950170-25-068203.md) | [15.2](/filings/0000950170-25-106022.md) | [14.9](/filings/0001193125-25-272324.md) | [15.0](/filings/0001193125-26-214700.md) | [14.8](/filings/0001193125-26-214700.md) |
| Total liabilities | $bn | [10.9](/filings/0000950170-23-040734.md) | [10.7](/filings/0000950170-23-062169.md) | [10.7](/filings/0000950170-25-030989.md) | [10.6](/filings/0000950170-24-065929.md) | [10.0](/filings/0000950170-24-094888.md) | [9.8](/filings/0000950170-24-125623.md) | [9.5](/filings/0001193125-26-073587.md) | [10.1](/filings/0000950170-25-068203.md) | [10.3](/filings/0000950170-25-106022.md) | [10.3](/filings/0001193125-25-272324.md) | [10.4](/filings/0001193125-26-214700.md) | [10.2](/filings/0001193125-26-214700.md) |
| Long-term debt | $bn | [10.2](/filings/0000950170-23-040734.md) | [10.2](/filings/0000950170-23-062169.md) | [10.1](/filings/0000950170-25-030989.md) | [10.1](/filings/0000950170-24-065929.md) | [9.4](/filings/0000950170-24-094888.md) | [9.2](/filings/0000950170-24-125623.md) | [8.8](/filings/0001193125-26-073587.md) | [9.5](/filings/0000950170-25-068203.md) | [9.6](/filings/0000950170-25-106022.md) | [9.6](/filings/0001193125-25-272324.md) | [9.7](/filings/0001193125-26-214700.md) | [9.7](/filings/0001193125-26-214700.md) |
| Shareholders' equity | $bn | [8.3](/filings/0000950170-23-040734.md) | [8.3](/filings/0000950170-23-062169.md) | [7.6](/filings/0000950170-25-030989.md) | [6.7](/filings/0000950170-24-065929.md) | [6.2](/filings/0000950170-24-094888.md) | [5.4](/filings/0000950170-24-125623.md) | [4.8](/filings/0001193125-26-073587.md) | [4.8](/filings/0000950170-25-068203.md) | [4.8](/filings/0000950170-25-106022.md) | [4.7](/filings/0001193125-25-272324.md) | [4.6](/filings/0001193125-26-214700.md) | [4.5](/filings/0001193125-26-214700.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [76.5 d](/filings/0000950170-24-094888.md) | [158 d](/filings/0000950170-24-125623.md) | [135 d](/filings/0001193125-26-073587.md) | [74.3](/filings/0000950170-25-068203.md) | [35.3 d](/filings/0000950170-25-106022.md) | [59.2 d](/filings/0001193125-25-272324.md) | [76.7 d](/filings/0001193125-26-073587.md) | [0.4](/filings/0001193125-26-214700.md) | [51.7 d](/filings/0000950170-25-106022.md) | [18.6 d](/filings/0001193125-25-272324.md) | [160 d](/filings/0001193125-26-073587.md) | [(14.3)](/filings/0001193125-26-214700.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [599](/filings/0000950170-23-040734.md) | [599](/filings/0000950170-23-062169.md) | [598](/filings/0000950170-24-065929.md) | [598](/filings/0000950170-24-094888.md) | [599](/filings/0000950170-24-125623.md) | [600](/filings/0000950170-25-068203.md) | [600](/filings/0000950170-25-106022.md) | [600](/filings/0001193125-25-272324.md) | [601](/filings/0001193125-26-214700.md) | [601](/filings/0000950170-25-106022.md) | [601](/filings/0001193125-25-272324.md) | [598](/filings/0001193125-26-214700.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 598,100,000 at 2026-05-06, from the cover of the [10-Q filed 2026-05-08](/filings/0001193125-26-214700.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.